Lipocine Inc.’s (LPCN) testosterone replacement therapy Tlando, which has been thrice rejected by the FDA, is trying its luck for the fourth, with a decision expected on August 28, 2020. Tlando, formerly known as LPCN 1021, is an oral testosterone product candidate that is designed to help restore normal testosterone levels in hypogonadal men.The regulatory agency had turned down Tlando in June 2016, May 2018, and in November 2019.It remains to be seen if Tlando will be able to get the FDA’s stamp of approval in its fourth try. In March of 2019, the FDA approved Clarus Therapeutics’ Jatenzo, an oral testosterone capsule to treat men with certain forms of hypogonadism.Lipocine is locked in a patent battle with Clarus claiming that Jatenzo infringes on four of its U.S. patents. In April, the U.S. Court of Appeals for the Federal Circuit ruled in favor of Lipocine in the patent infringement lawsuit.LPCN closed Friday’s (Jul.24, 2020) trading at $1.48.